Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | January 24, 2011 |
| Target | BioVex Group |
| Sector | Life Science |
| Buyer(s) | Amgen |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.0B USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1980 |
| Sector | Life Science |
| Employees | 28,000 |
| Revenue | 33.4B USD (2024) |
Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.
| Deal Context for Buyer | # |
|---|---|
| Overall | 8 of 21 |
| Sector: Life Science | 8 of 20 |
| Type: Add-on Acquisition | 8 of 20 |
| State: Massachusetts | 3 of 3 |
| Country: United States | 8 of 16 |
| Year: 2011 | 1 of 2 |
| Size (of disclosed) | 10 of 20 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-06-06 |
Alantos Pharmaceuticals Holding
Cambridge, Massachusetts, United States Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company with a proprietary pipeline of small molecule drugs focused in the area of type II diabetes and osteoarthritis / inflammation. With locations in Cambridge, Massachusetts and Heidelberg, Germany, Alantos Pharmaceuticals employs 45 people. |
Buy | $300M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-04-08 |
Bergamo
Sao Paulo, Brazil Bergamo is a supplier of medicines to the hospital sector in Brazil with capabilities in oncology medicines and has manufacturing facilities in Sao Paulo state. |
Buy | $215M |
